Tiny RNA therapies to stop unwanted bone after injury
Small RNA Targeting Approaches to Advance Treatments for Heterotopic Ossification
Testing nanoparticle-delivered small RNAs to prevent or reduce extra bone growth after traumatic injuries, orthopedic surgery, or burns.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11196222 on NIH RePORTER |
What this research studies
From my perspective as someone worried about extra bone after an injury, the team is developing tiny RNA molecules (microRNA and siRNA) packaged in nanoparticles to block the signals that cause bone to form in muscles, tendons, and ligaments. They will use a mouse model that mimics trauma-induced heterotopic ossification to deliver these RNA therapies and measure whether abnormal bone is reduced. The researchers are focusing on a specific microRNA (miR-138) and a target called RhoC, and will study how inflammation and cytoskeletal pathways drive early bone formation. The work aims to identify approaches that could eventually be tested in people to prevent disability from HO.
Who could benefit from this research
Good fit: People who develop or are at high risk for heterotopic ossification after traumatic injuries, major burns, or certain orthopedic procedures would be ideal candidates for future trials.
Not a fit: Patients with long-established, fully matured heterotopic bone that is already ossified may not benefit from these early-stage molecular therapies.
Why it matters
Potential benefit: If successful, this could lead to new treatments that prevent or shrink heterotopic bone, helping preserve motion, reduce pain, and avoid additional surgeries.
How similar studies have performed: Prior lab and mouse work showed miR-138 can inhibit bone formation and RhoC suppression reduces osteogenesis, but using nanoparticle small‑RNA therapies for trauma-induced HO in vivo is largely new.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Mcalinden, Audrey — Washington University
- Study coordinator: Mcalinden, Audrey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.